Verona Pharma Plc ADR (NASDAQ:VRNA) price on Friday, April 19, fall -2.36% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $15.72.
A look at the stock’s price movement, the close in the last trading session was $16.10. Turning to its 52-week performance, $23.81 and $11.83 were the 52-week high and 52-week low respectively. Overall, VRNA moved -1.32% over the past month.
Verona Pharma Plc ADR’s market cap currently stands at around $1.26 billion.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that VRNA is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
VRNA’s current price about -3.09% and -4.81% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.99, while 7-day volatility ratio is 3.66% and 4.08% in the 30-day chart. Further, Verona Pharma Plc ADR (VRNA) has a beta value of 0.42, and an average true range (ATR) of 0.69.
If we refocus on Verona Pharma Plc ADR (NASDAQ:VRNA), historical trading data shows that trading volumes averaged 442.91K over the past 3 months. The company’s latest data on shares outstanding shows there are 80.44 million shares.
The 23.41% of Verona Pharma Plc ADR’s shares are in the hands of company insiders while institutional holders own 61.41% of the company’s shares. Current price change has pushed the stock -20.93% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VRNA stock continues to rise going into the next quarter.
